Bactroban Nasal Now Available for the Eradication of MRSAContact Us | Order Now | Journals |Bookstore | Register a colleague PHILADELPHIA, April 30, 1996 -- SmithKline Beecham announced today that Bactroban(R) Nasal (mupirocin calcium ointment), 2%, which recently was cleared for marketing by the U.S. Food and Drug Administration (FDA), now is available nationwide. Bactroban Nasal is a new formulation of the company's topical antibiotic, Bactroban (mupirocin). Bactroban Nasal is the first intranasally administered topical agent shown to be effective in the eradication of nasal colonization with methicillin-resistant Staphylococcus aureus (MRSA) in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of MRSA infection during institutional outbreaks of infections with this pathogen. A problem first confined to tertiary care centers and large teaching hospitals, MRSA outbreaks increasingly affect hospitals and other health care institutions of all sizes and, once established, have proven extremely difficult to eradicate.
